|
Core Support for Cancer Center
|
3P30CA013330-43S1
|
$199,871
|
$13,991
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Core Support for Cancer Center
|
5P30CA013330-42
|
|
$0
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Core Support for Cancer Center
|
6P30CA013330-43
|
$3,696,138
|
$258,730
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Treating pancreatic cancer with Listeria-32P
|
1R21CA199010-01
|
$16,676
|
$16,676
|
GRAVEKAMP, CLAUDIA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Treating pancreatic cancer with Listeria-32P
|
6R21CA199010-02
|
$201,259
|
$201,259
|
GRAVEKAMP, CLAUDIA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Deciphering the Tissue Specificity of MEN1 Related Tumorigenesis
|
5R01CA170911-04
|
|
$0
|
LIBUTTI, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Deciphering the Tissue Specificity of MEN1 Related Tumorigenesis
|
6R01CA170911-05
|
$346,525
|
$173,263
|
LIBUTTI, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Tumor expressed B7x accelerates disease and is a novel target for immunotherapy
|
6F31CA183493-02
|
$47,676
|
$23,838
|
OHAEGBULAM, KIM
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Interactions of the angiopoietin and PD-ECGF pathways in tumor angiogenesis
|
5R01CA163907-04
|
|
$0
|
SCHWARTZ, EDWARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Interactions of the angiopoietin and PD-ECGF pathways in tumor angiogenesis
|
6R01CA163907-05
|
$346,525
|
$346,525
|
SCHWARTZ, EDWARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
BASE PERIOD: STUDY INITIATION (09/30/2015 - 12/29/2015)
|
261201500022C
|
$137,084
|
$137,084
|
UNKNOWN, UNKNOWN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-02
|
$28,106
|
$7,027
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
The B7x pathway in the tumor microenvironment
|
6R01CA175495-03
|
$318,419
|
$79,605
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Enhancing T Cell Therapy of Cancer
|
5P01CA094237-13
|
$1,932,287
|
$483,072
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Advanced Glycation End-Products and Risk of Pancreatic Cancer
|
5R01CA172880-03
|
$498,656
|
$498,656
|
JIAO, LI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
2P30CA125123-09
|
$3,155,163
|
$220,861
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-09S2
|
$112,151
|
$7,851
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-09S3
|
$183,048
|
$12,813
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
1R01CA183984-01A1
|
$472,669
|
$472,669
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Prospective Investigation of the Oral Microbiome and Pancreatic Cancer
|
1U01CA187508-01A1
|
$498,385
|
$498,385
|
PALMER, JULIE
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-02S1
|
$34,176
|
$1,709
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-02S2
|
$810,357
|
$40,518
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-02
|
$9,967,453
|
$498,373
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Systematic identification of oncogenic KRAS synthetic lethal interactions
|
1U01CA199253-01
|
$817,805
|
$269,876
|
HAHN, WILLIAM
|
BROAD INSTITUTE, INC.
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
3U10CA180853-01S1
|
$171,796
|
$4,295
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-02
|
$1,360,245
|
$34,006
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Next-generation mouse gene-targeting technology to model tumorigenesis
|
5R21CA181859-03
|
$206,843
|
$68,258
|
WANG, ZHENGHE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Molecular Mechanisms of BRCA1-Dependent DNA Damage Response and Tumorogenesis
|
7R01CA132755-08
|
$31,739
|
$10,474
|
YU, XIAOCHUN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Development of an ADC against Pancreatic Cancer
|
1R43CA189436-01A1
|
$225,000
|
$225,000
|
SCHLOSSER, MICHAEL
|
COARE BIOTECHNOLOGY, INC.
|
|
Finding Novel Pancreatic Cancer Oncogenes Using an Innovative 3D Culture System
|
1F32CA192904-01
|
$54,194
|
$54,194
|
BAKER, LINDSEY
|
COLD SPRING HARBOR LABORATORY
|
|
The Characterization of the New Tumor Suppressor USP9X in Pancreatic Cancer
|
1F32CA180717-01A1
|
$56,042
|
$56,042
|
HWANG, CHANG-IL
|
COLD SPRING HARBOR LABORATORY
|
|
2/2 Partnership to Study Racial/Ethnic Differences in GI Cancer Biology
|
1P20CA192996-01A1
|
$155,520
|
$101,088
|
MCCOMBIE, WILLIAM
|
COLD SPRING HARBOR LABORATORY
|
|
Cold Spring Harbor Laboratory Cancer Research Center
|
5P01CA013106-44
|
$4,421,268
|
$221,063
|
STILLMAN, BRUCE
|
COLD SPRING HARBOR LABORATORY
|
|
CSHL CANCER CENTER SUPPORT GRANT
|
5P30CA045508-28
|
$4,418,824
|
$397,694
|
STILLMAN, BRUCE
|
COLD SPRING HARBOR LABORATORY
|
|
(PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer
|
5R01CA190092-02
|
$555,711
|
$555,711
|
TUVESON, DAVID
|
COLD SPRING HARBOR LABORATORY
|
|
Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer
|
1R44CA200186-01A1
|
$280,588
|
$280,588
|
MCMURRY, THOMAS
|
COLLAGEN MEDICAL, LLC
|
|
Chemical genetic profiling of engineered tumor cells
|
5R01CA097061-12
|
$350,176
|
$350,176
|
STOCKWELL, BRENT
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
Genetic and pharmacological manipulation of system xc in pancreatic cancer
|
5F31CA180738-02
|
$43,120
|
$43,120
|
BADGLEY, MICHAEL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-41S1
|
$120,000
|
$7,200
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-41S2
|
$60,000
|
$3,600
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-41S3
|
$125,000
|
$7,500
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-41S4
|
$157,133
|
$9,428
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-41
|
$3,792,720
|
$227,563
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Mechanisms of the Stromal Response to Smoothened Inhibition in Pancreatic Cancer
|
5R01CA157980-05
|
$334,075
|
$334,075
|
OLIVE, KENNETH
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Preclinical evaluation of a targeted Bmi1 inhibitor in pancreatic cancer
|
5R21CA188857-02
|
$172,340
|
$172,340
|
OLIVE, KENNETH
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The role of wild-type KRAS in the context of tumor profession and metastasis
|
1R01CA178445-01A1
|
$409,343
|
$409,343
|
SU, GLORIA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Mouse Model for Human Pancreatic Ductal Adenocarcinoma
|
5R01CA109525-11
|
$250,358
|
$250,358
|
SU, GLORIA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The role of fibroblasts in the activities of tissue penetrating peptides
|
5R01CA167174-05
|
$378,202
|
$189,101
|
SUGAHARA, KAZUKI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Long non-coding RNAs in pancreatic cancer
|
5R21CA188059-02
|
$174,000
|
$174,000
|
SUSSEL, LORI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Myofibroblasts in Gastrointestinal Cancers
|
5U54CA163111-05
|
$501,771
|
$150,531
|
WANG, TIMOTHY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
Total relevant funding to Pancreas for this search: $125,247,562
|